Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial
Authors
Keywords
-
Journal
INTENSIVE CARE MEDICINE
Volume 47, Issue 8, Pages 867-886
Publisher
Springer Science and Business Media LLC
Online
2021-07-12
DOI
10.1007/s00134-021-06448-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
- (2021) NEW ENGLAND JOURNAL OF MEDICINE
- Platform Trials — Beware the Noncomparable Control Group
- (2021) Lori E. Dodd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials
- (2021) Cathrine Axfors et al. Nature Communications
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
- (2020) Manli Wang et al. CELL RESEARCH
- Severe SARS-CoV-2 infections: practical considerations and management strategy for intensivists
- (2020) Lila Bouadma et al. INTENSIVE CARE MEDICINE
- Critical care management of adults with community-acquired severe respiratory viral infection
- (2020) Yaseen M. Arabi et al. INTENSIVE CARE MEDICINE
- In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
- (2020) Xueting Yao et al. CLINICAL INFECTIOUS DISEASES
- Prioritisation of Anti‐SARS‐Cov‐2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics
- (2020) Usman Arshad et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- 15-day mortality and associated risk factors for hospitalized patients with COVID-19 in Wuhan, China: an ambispective observational cohort study
- (2020) Ke Wang et al. INTENSIVE CARE MEDICINE
- Clinicolaboratory study of 25 fatal cases of COVID-19 in Wuhan
- (2020) Wen-Jun Tu et al. INTENSIVE CARE MEDICINE
- Autophagy inhibition by chloroquine and hydroxychloroquine could adversely affect acute kidney injury and other organ injury in critically ill patients with COVID-19
- (2020) Charles L. Edelstein et al. KIDNEY INTERNATIONAL
- Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets
- (2020) Su-Jin Park et al. mBio
- Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic: rapid review
- (2020) Andrew Dagens et al. BMJ-British Medical Journal
- Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)
- (2020) Katelyn A Pastick et al. Open Forum Infectious Diseases
- Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations
- (2020) Catia Marzolini et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
- (2020) Ka-Tim Choy et al. ANTIVIRAL RESEARCH
- Hydroxychloroquine pharmacokinetic in COVID-19 critically ill patients: an observational cohort study
- (2020) Benoit Painvin et al. INTENSIVE CARE MEDICINE
- A multicenter national survey of children with SARS-CoV-2 infection admitted to Spanish Pediatric Intensive Care Units
- (2020) Rafael González Cortés et al. INTENSIVE CARE MEDICINE
- Emerging pharmacological therapies for ARDS: COVID-19 and beyond
- (2020) Shahd Horie et al. INTENSIVE CARE MEDICINE
- How likely are COVID-19 interventions to benefit the sickest patients?
- (2020) Anders Perner et al. INTENSIVE CARE MEDICINE
- A minimal common outcome measure set for COVID-19 clinical research
- (2020) John C Marshall et al. LANCET INFECTIOUS DISEASES
- Drug treatments for covid-19: living systematic review and network meta-analysis
- (2020) Reed AC Siemieniuk et al. BMJ-British Medical Journal
- Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19
- (2020) et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- Interferon Beta-1b and Lopinavir–Ritonavir for Middle East Respiratory Syndrome
- (2020) Yaseen M. Arabi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Correction: COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology
- (2020) PLOS MEDICINE
- Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Selepressin vs Placebo on Ventilator- and Vasopressor-Free Days in Patients With Septic Shock
- (2019) Pierre-Francois Laterre et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Bayesian Analysis: Using Prior Information to Interpret the Results of Clinical Trials
- (2017) Melanie Quintana et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset
- (2015) Jasper Fuk-Woo Chan et al. JOURNAL OF INFECTIOUS DISEASES
- Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture
- (2014) Adriaan H. de Wilde et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics of Lopinavir/Ritonavir Crushed Versus Whole Tablets in Children
- (2011) Brookie M. Best et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started